What is Nevolat

Nevolat is a prescription-only medicine used for weight management in adults, alongside a reduced-calorie diet and increased physical activity. It contains liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.

Liraglutide works by mimicking a naturally occurring hormone called GLP-1, which helps regulate appetite and food intake. It acts on areas of the brain that control hunger, helping you feel fuller and reducing the desire to eat.

It is administered as a once-daily injection, with dosing increased gradually to reach a maintenance dose. This stepwise approach helps the body adjust and may reduce the likelihood of gastrointestinal side effects.

Weight management outcomes vary between individuals, and ongoing lifestyle measures remain an important part of treatment.

Who Liraglutide is for

Liraglutide is indicated for weight management in adults aged 18 to 75 years when used alongside a reduced-calorie diet and increased physical activity.

It may be suitable for individuals who:

• have not achieved sufficient weight loss through dietary changes and increased physical activity alone, and
• meet one of the following criteria:
  • Body Mass Index (BMI) of 30 kg/m² or higher, or
  • BMI of 27 kg/m² or higher with at least one weight-related condition, such as:
    • Hypertension
    • Dyslipidaemia
    • Obstructive sleep apnoea
    • Type 2 diabetes

Dosage

Liraglutide is administered as a once-daily subcutaneous injection.

Treatment is started at a low dose and increased gradually each week until the recommended maintenance dose is reached. This gradual increase helps to improve tolerability.

The injection can be taken at any time of day, with or without food, but should be taken at approximately the same time each day.

If a dose is missed, it should be taken as soon as possible on the same day. A double dose should not be taken to make up for a missed dose.

For individuals with a BMI above 50 kg/m², additional medical supervision may be appropriate as part of overall weight management.

Liraglutide is the active ingredient in the branded medicine Saxenda. Nevolat contains the same active substance.

Patient information leaflet

Our service does not include a prescription. Instead, your treatment will be supplied under a legal framework called Patient Group Direction (PGD), and the process will follow these steps:

1. Complete a health questionnaire:

Provide detailed information about your health, medical history, and previous weight management attempts.

2. Pharmacist assessment:

Our pharmacist will review your responses and may reach out via phone or video call to confirm your suitability for Mounjaro.

3. Private consultation:

All consultations are private and confidential. This gives you the opportunity to ask questions and ensure Mounjaro is the right choice for your needs.

4. All-inclusive pricing:

The price you pay includes the consultation fee, with no hidden costs.

5. Identity verification:

You'll need to provide identification during the consultation to confirm that you are the intended user. This is required only during your first order.

6. Photographic evidence request:

You’ll be asked to submit photographic evidence of your weight, height, and relevant medical history to ensure safe and accurate consultation.

Purchasing this medication does not guarantee its supply. The decision if this medication is right for you will be made together with the pharmacist during your consultation, and ultimately the decision to supply the medication is with the pharmacist. Any orders found not suitable will be refunded.

Active ingredient: liraglutide. 1 ml solution for injection contains 6 mg liraglutide. One pre-filled pen contains 18 mg liraglutide.

Other ingredients: sodium citrate dihydrate, propylene glycol, phenol, water for injection, hydrochloric acid and/or sodium hydroxide solution.

Patient information leaflet

The starting dose is 0.6 mg once daily.
The dose should be increased to 3.0 mg once daily in increments of 0.6 mg with at least one-week intervals to improve gastrointestinal tolerability (see Table).
If escalation to the next dose step is not tolerated for two consecutive weeks, consider discontinuing treatment.
Daily doses higher than 3.0 mg are not recommended.

Dose Escalation Schedule (4 weeks)

Liraglutide should not be used in people allergic to its ingredients or in those with severe heart failure (NYHA IV).

It is not recommended for:

• patients aged 75+,
• people with severe liver or kidney problems
• those using other weight-loss drugs.

Use cautiously in people with mild to moderate liver issues, thyroid disease, or gastrointestinal disorders such as gastroparesis. It may cause nausea, vomiting, diarrhoea, gallstones, or pancreatitis. Stop treatment if pancreatitis occurs.

Monitor for increased heart rate and dehydration. Liraglutide can interact with insulin, sulfonylureas, warfarin, digoxin, lisinopril, and oral contraceptives, though most effects are minor.

Avoid use during pregnancy and breastfeeding. It may slightly affect fertility in animals.

May cause dizziness during the first months of treatment; caution is advised when driving or operating machinery.